Japanese CRO JCL Bioassay Sales And Profits Increase
This article was originally published in PharmAsia News
Japanese contract research organization JCL Bioassay announced April 30 results for FY2008. The company achieved a record ¥2.48 billion in sales, a 7 percent increase. The company's business profit increased by 40.6 percent to ¥502 million, regular profit increased by 32.3 percent to ¥437 million, and net profit increased by 11.3 percent to ¥259 million. Bioanalysis service accounts for 80 percent of JCL Bioassay's sales. For the fiscal year 2009, JCL Bioassay estimates sales, business profit and regular profit increases by 3.5, 11.2 and 3.8 percent, respectively. The company cites a continuous outsourcing trend in pharmaceutical companies. (Click here for more - Japanese language
You may also be interested in...
The EU has published an action plan that is intended to upgrade the bloc’s intellectual property framework while ensuring that goods such as medicines and vaccines are made as widely available as possible. The initiative is part of wide-ranging plans to support member states’ recovery from the pandemic crisis and help ensure the EU’s resilience to future health threats.
Execs On The Move: New CEO For Humacyte; Internal Moves At Trinity Biotech, CVRx, Oventus Medical And Cancer Genetics
Trinity Biotech's new CFO is an internal move; Humacyte replaces CEO; chief strategy officer role for former CVRx CFO; and more.
Teva received a “package of commercial side-deals” for agreeing to halt generic competition to Cephalon’s Provigil (modafinil) throughout the EU, which it “would not have achieved without committing to staying out of the market,” according to findings by the European Commission.